<DOC>
	<DOCNO>NCT01419197</DOCNO>
	<brief_summary>This randomize , multicenter , 2-arm , open-label study ( TH3RESA ) evaluate efficacy safety trastuzumab emtansine ( T-DM1 ) comparison treatment physician 's choice participant metastatic unresectable locally advanced/recurrent human epidermal growth factor receptor 2 ( HER2 ) -positive breast cancer . Eligible participant randomize receive either trastuzumab emtansine 3.6 mg/kg intravenously every 21 day treatment physician 's choice . Participants continue receive study treatment disease progression unacceptable toxicity occur . This study also know Roche study protocol number BO25734 .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine Comparison With Treatment Physician 's Choice Participants With HER2-positive Breast Cancer Who Have Received Least Two Prior Regimens HER2-directed Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Adult participant ≥ 18 year age . Histologically cytologically document breast cancer . Metastatic unresectable locally advanced/recurrent breast cancer . HER2positive disease prospective laboratory confirmation . Disease progression last regimen receive defined investigator . Prior treatment trastuzumab , taxane , lapatinib . Disease progression least two regimen HER2directed therapy metastatic unresectable locally advanced/recurrent set . Adequate organ function , evidence laboratory result . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Left ventricular ejection fraction ( LVEF ) ≥ 50 % echocardiogram multi gate acquisition scan . Chemotherapy ≤ 21 day first study treatment . Trastuzumab ≤ 21 day first study treatment . Lapatinib ≤ 14 day first study treatment . Prior enrollment trastuzumab emtansine contain study , regardless whether patient receive prior trastuzumab emtansine . Brain metastasis untreated symptomatic , require radiation , surgery corticosteroid therapy control symptom within 1 month randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>